Vasectomy is highly effective, and the prostate-cancer scare doesn't hold up

Vasectomy is one of the most reliable forms of contraception available, using vas-occlusion techniques with failure rates consistently below 1%, and the long-running worry that it causes prostate cancer does not hold up for the cancers that actually kill men [s1][s2]. The most rigorous review to date — 53 studies pooling millions of men — found no association between vasectomy and high-grade, advanced-stage, or fatal prostate cancer, and only a weak link to any diagnosis that faded as study quality improved [s2].

How well it works

A vasectomy cuts or seals the vas deferens so sperm cannot reach the semen. The American Urological Association's guideline, built from a systematic review of the literature, recommends isolating the vas with a minimally invasive method such as the no-scalpel technique, and lists four occlusion methods whose failure rates are consistently under 1% [s1]. Crucially, the procedure is not effective immediately: a man must keep using other contraception until a follow-up semen analysis confirms the sperm are gone [s1]. The guideline also stresses that vasectomy should be counselled as a permanent method — reversal is possible but not guaranteed, and is not the plan a man should rely on [s1].

The prostate-cancer question, answered honestly

The fear that vasectomy causes prostate cancer has circulated for three decades, and the honest answer is that the evidence is reassuring but not perfectly clean.

The strongest synthesis is a 2017 meta-analysis of 53 studies — 16 cohort studies covering 2,563,519 participants, 33 case-control studies, and 4 cross-sectional studies [s2]. Among the studies at lowest risk of bias, vasectomy carried a barely detectable excess of any prostate cancer diagnosis: an adjusted rate ratio of 1.05 (95% CI, 1.02–1.09) in cohort studies, and a non-significant 1.06 (0.88–1.29) in case-control studies [s2]. The association grew larger only when weaker studies were added — a classic signature of bias rather than cause [s2]. And for the outcomes that matter most, there was nothing: no significant link to high-grade (rate ratio 1.03), advanced (1.08) or fatal (1.02) prostate cancer [s2]. The authors put the absolute lifetime excess at 0.6% (95% CI, 0.3–1.2), with a population-attributable fraction of just 0.5% (95% CI, 0.2–0.9), and concluded the link is unlikely to be causal and should not deter men from choosing vasectomy [s2]. That review was not a quick scan of the field: it pooled 53 studies drawn from four databases, weighing cohort, case-control and cross-sectional designs separately precisely because the weaker designs were where the apparent risk lived [s2].

Why a huge registry still sees a signal

The counterweight is a Danish study that followed 2,150,162 men over 53.4 million person-years, during which 26,238 prostate cancers occurred [s3]. It found vasectomised men had a 15% higher rate of prostate cancer (relative risk 1.15; 95% CI, 1.10–1.20), an excess that persisted for at least 30 years and held regardless of age at the procedure or the stage at diagnosis [s3]. The researchers even adjusted for how often men visited the doctor and for socioeconomic factors, and the association did not disappear [s3].

How to square the two? The most likely explanation is detection: men who have had a vasectomy are already in contact with urology services and may be tested and biopsied more, surfacing cancers that would otherwise have gone unnoticed — the same overdiagnosis dynamic that dogs PSA screening. The Danish authors adjusted for doctor visits and still saw the signal, so they cannot rule out a real, small effect. But the decisive point for a man weighing the decision is the one both analyses agree on: even taken at face value, the absolute increase is small, and there is no link to the aggressive, life-threatening disease [s2][s3].

What it means

For contraception, vasectomy is about as effective as a reversible method gets once a semen test has confirmed it worked, and it should be treated as permanent [s1]. The prostate-cancer worry, examined across tens of millions of men, comes down to at most a small excess of low-grade diagnoses that most experts attribute to extra testing, with no signal for the cancers that kill [s2][s3]. Chronic scrotal pain is a recognised, if uncommon, complication that the guideline says men should be counselled about beforehand [s1]. What is not in genuine dispute is the headline a generation of scares obscured: this is a safe, highly effective procedure whose cancer risk, if any, is trivial.

Sources

• [s1] Journal of Urology (AUA) — Vasectomy: AUA Guideline (2012-10-24)
• [s2] JAMA Internal Medicine — The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis (2017-07-17)
• [s3] JNCI: Journal of the National Cancer Institute — Vasectomy and Prostate Cancer Risk: A 38-Year Nationwide Cohort Study (2019-05-23)